An interventional study of General information and Baseline brief intervention in Fetal Alcohol Spectrum Disorders, Fetal Alcohol Syndrome and Fetal Alcohol Effect, sponsored by Michigan State University. Completed at 1 site in United States. Open to female participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by Michigan State University · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Fetal Alcohol Spectrum Disorders with a site in United States — 10 open to participants now, 11 under way, none of them phase 3. Fetal Alcohol Spectrum Disorders · United States.
Among the 37 studies in Fetal Alcohol Spectrum Disorders with a site in United States, this one is the 5th largest by enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2023, is one of 22 with no phase, and was the 22nd registered.
65 studies on the registry are indexed under Fetal Alcohol Spectrum Disorders; 13 are open to participants now.
Browse Fetal Alcohol Spectrum Disorders studies →10 of the 37 studies in Fetal Alcohol Spectrum Disorders with a site in United States are open now. Recruiting first, the newest first:
University of Virginia · Sites in United States
Ages 18–44 · Women only · Healthy volunteers
University of Rochester · Sites in United States
Ages 18–25
Stanford University · Sites in United States
Ages 18–40 · Healthy volunteers
University of California, Los Angeles · Sites in United States
Ages 8–12
University of Rochester · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Fetal Alcohol Spectrum Disorders studies recruiting now, 4 (33%) set no upper age limit and 8 (67%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 35 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 8 · Phase 3 1
First in 2001; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 384 is above the median of 74 across 57 interventional studies indexed under Fetal Alcohol Spectrum Disorders.
Median enrollment 85 across the 34 interventional studies, 751 across the 3 observational. Of the 26 that completed or were terminated, 10 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 37 has an industry lead sponsor. The 10 most frequent:
Michigan State University is the lead sponsor of 143 studies on the registry; 27 are open to participants now.
Michigan State University has 1 study filed under Fetal Alcohol Spectrum Disorders — fewer than ten, so there is no comparison to draw.
6 of the studies in Fetal Alcohol Spectrum Disorders with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06847165University of California, Los AngelesTrigeminal Nerve Stimulation for Children With Prenatal Alcohol Exposure | 2026-12-29 |
| NCT06635746Stanford UniversityDose Escalation Study of Vinpocetine in Healthy Volunteers | 2026-12-31 |
| NCT06638463University of RochesterMy Health Coach App RCT | 2026-12-31 |
| NCT05960461University of RochesterFamilies Moving Forward (FMF) Connect Pro for Mental Health Providers | 2027-04-30 |
| NCT05456321University of MinnesotaCIFASD 5 tDCS and Cognitive Training | 2027-05-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 37 studies in Fetal Alcohol Spectrum Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research study is to find out if pregnant women screening positive for alcohol risk like the brief alcohol intervention application that the investigators have developed (called the MommyCheckup, which is a technology-delivered SBIRT, or e-SBIRT), and if it helps them to reduce alcohol use. The investigators also wish to test whether e-SBIRT effects can be enhanced by booster sessions and/or tailored text messages.
This factorial trial will include 384 participants. Participants will be pregnant women age 18-35 years who score positive on a frequently used and well-validated screening tool for alcohol use risk in pregnancy (the T-ACE). We will also add an additional requirement of either drinking weekly or more in the past month, or having 4 or more drinks at a time at least monthly in the 12 months before becoming pregnant. To be eligible for the study, participants must also report smartphone ownership, willingness to receive study-related text messages and to use their smartphone for study-related assessments and/or booster sessions, and being at 20 weeks gestation or less. Participants will be excluded if they are not planning to carry the pregnancy to term, or are unable to communicate in English. All participants must reside in Connecticut, Massachusetts, or Michigan. Completion of the baseline assessment is also necessary for inclusion.
Participants will be recruited via community flyers as well as by online posts, flyers, and other advertising via multiple digital platforms that may appear as banners, text, images, video, and/or URL links to the study website, which further links to the screening survey.. The flyers and ads will contain basic information indicating that they are for a health-related study for women 18-35 years of age who can communicate in English. Interested women meeting these criteria will be provided a website address, QR code, or link to a study website, where they will be presented with an electronic information sheet, which they may access via their own smartphone or tablet. Those who click "I agree" at the end of this information sheet, will be invited to complete the initial computer-directed screening survey via a link from the study website to a Qualtrics survey. This survey will ask a range of questions so that the study's inclusion and exclusion criteria are not readily apparent (in order to limit fraud).
The screening survey will be used to determine whether initial inclusion criteria have been met [(age, state of residence, pregnancy status, and alcohol risk (T-ACE positive and either drinking weekly or more in the past month, or having 4 or more drinks at a time at least monthly in the 12 months before becoming pregnant)]. Study staff will contact interested women who meet study inclusion criteria by phone in order to validate their eligibility (survey completed by a real person, who can communicate in English, has a working smartphone, is able to receive text messages, and understands study requirements). The following strategies will be implemented to reduce the possibility of fraudulent participation: 1) manual review of IP addresses to screen for duplicates and identify addresses of non-US origin, detect fraudulent completion (e.g., bots), 2) manual review of Qualtrics survey data to detect suspicious response times (e.g., completing the survey too quickly), unusual patterns in responses, respondent names, respondent email addresses, and patterned completion timestamps indicating that one person/bot is completing the survey repeatedly until eligible, 3) inclusion of a required open-ended narrative response to detect fraudulent completion, and 4) inclusion of invisible questions that only a bot could respond to, as well as visible nonsense questions directing the respondent to provide a particular answer. Only interested women who pass these screens and can be confirmed via the phone call will be enrolled.
The full trial consent will also be presented electronically and will proceed only if participants provide written informed consent via e-signature (using DocuSign, see section 10.1.3 of the protocol for additional information). Participants who meet all eligibility criteria and who provide consent will then be randomly assigned to a study condition during the baseline assessment. The staff member who enrolls the participant will not have access to the assigned condition/content at the time of consent and initial study condition assignment.
This trial includes varying levels of two separate interventions. The interactive and tailored baseline MommyCheckup single-session e-SBIRT was built on principles of Motivational Interviewing and Self-Determination Theory, and is presented to participants directly via their own electronic device (e.g., smartphone, tablet), which interacts with them through an animated talking narrator. The e-SBIRT booster sessions will be sent to participants as a text message that includes a link to the booster content. Participants will be texted these links on two occasions: 6 weeks following the baseline session, and at 30 weeks gestation. Participants assigned to the text messaging intervention will receive a test message at the conclusion of their baseline session, in order to confirm that the software has the correct cellphone number. These participants will then begin receiving text messages twice weekly until after the 34-week assessment, or until they text back "STOP" to end the messages.
Following the baseline session, participants will be asked to complete follow-up assessments at 4 weeks post-baseline, at 27 weeks gestation, 34 weeks gestation, and at 4 weeks postpartum. In addition, all participants will be mailed a nail specimen collection kit at 36 weeks gestation asking them to provide nail clippings that will be analyzed for Ethyl Glucuronide (EtG). Fingernails will be collected at 36 weeks gestation. Toenails may be collected at 38 weeks gestation as an alternative to fingernails. Nail types may not be mixed for a single specimen collection. Specimens from all available fingernails or toenails weighing 50-100 mg gathered at 36 weeks (fingernails) or 38 weeks (toenails) will allow for sufficient nail growth to capture EtG as evidence of alcohol use concentrated in the timeframe of approximately 20-34 weeks gestation, based on typical fingernail and toenail growth rates. Additionally, this timeframe will allow us to avoid detecting post-delivery alcohol use since it takes approximately two weeks for fingernails and four weeks for toenails to grow sufficiently for detectability. Participants will be reminded of the upcoming nail specimen collection at their 27-week and 34-week data collections, plus reminders will be included when the survey links are sent by text for these data collection timepoints. In the event of preterm birth, nail specimens will be requested immediately. The level of detectability for either nail type will be set at 8 pg/mg, which is the lower level of quantitation used for research (the standard level of detectability used for non-research testing is 20 pg/mg). (NOTE: Biospecimen (nails) collection was discontinued as of 9/30/2025 and specimens were not analyzed after the first 59 samples.)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Control, which includes treatment as usual plus referral resources
Other: General information
SMS refers to tailored text messaging.
Other: General information · Behavioral: SMS
Brief technology-delivered intervention for alcohol use during pregnancy
Behavioral: Baseline brief intervention
Brief technology-delivered intervention for alcohol use during pregnancy, plus tailored text messaging
Behavioral: Baseline brief intervention · Behavioral: SMS
Brief technology-delivered intervention for alcohol use during pregnancy, plus two very brief (\<5 minutes) online boosters using the participants' own mobile device.
Behavioral: Baseline brief intervention · Behavioral: Remote online booster sessions
Brief technology-delivered intervention for alcohol use during pregnancy, plus two very brief (\<5 minutes) online boosters using the participants' own mobile device, plus tailored SMS.
Behavioral: Baseline brief intervention · Behavioral: Remote online booster sessions · Behavioral: SMS
General information related to pregnancy is provided electronically.
Interactive brief motivational intervention is delivered electronically. Provides an introduction, describing the purpose and duration, emphasizing the non-judgmental nature of the brief intervention (BI). Uses a high-quality video featuring gain-framed messaging, quit recommendation, and testimonial from a race-matched woman; tailored on race-ethnicity, efficacy, binge frequency, and level of concern regarding her own alcohol use. The e-BI poses a question regarding the participant's willingness to avoid alcohol throughout her pregnancy. Responses to this question will sort participants into one of three major branches, each using motivational principles to promote alcohol abstinence during pregnancy.
Two \< 5-minute online e-BI boosters will be sent to participants via text link (one at 6 weeks post-baseline and one at 30 weeks gestation). The boosters will include a brief summary of the prior session in terms of the participant's concerns and goals. It will also include an assessment of her current status regarding (a) use of alcohol, and (b) intentions regarding future use of alcohol. A brief (1-2 minute) video tailored on her current status and prior goal will be provided. Finally, the boosters will contain optional goal-setting regarding reaching or maintaining abstinence.
Tailored text messages (SMS) will be sent to participants twice a week from baseline throughout her pregnancy (or until she opts out). The messages will be tailored on her quit status, goals, efficacy, level of concern, gestation, and perceived advantages of change. Messages will follow current state of the art regarding messaging preferences, tailoring, and gain-framing. The current list includes messages regarding fetal development, nutrition, exercise, and stress management, as well as alcohol.
Number of Participants Abstinent From Alcohol as Measured by Timeline FollowBack Calendar Recall
The primary outcome of abstinence will be defined as no self-report of alcohol use in the past 90 days via Timeline FollowBack, measured at 34 weeks gestation.
Time frame: 90 days prior to 34 weeks gestation
Number of Participants With a Healthy Birth Outcome (Full-term Live Birth of Normal Birthweight, With no Days in NICU)
Healthy birth outcome, using birth outcome data from the state of birth, is defined as a full-term live birth (\>=36 weeks + 6 days) of normal birthweight (\>2500 gms) and with no days in neonatal intensive care.
Time frame: Measured at birth, which was up to 42 weeks gestation
Participants were recruited between May 2023 and October 2024 from throughout the United States via ads placed on social media (Facebook and Instagram) and flyers distributed at prenatal care clinics in Michigan and Massachusetts.
| Milestone | General Information | General Information + SMS | Baseline Brief Intervention | Baseline Brief Intervention + SMS | Baseline Brief Intervention + 2 Booster Sessions | Baseline Brief Intervention + 2 Booster Sessions + SMS |
|---|---|---|---|---|---|---|
| Started | 63 | 66 | 63 | 66 | 63 | 63 |
| Completed | 63 | 66 | 63 | 66 | 63 | 63 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | General Information | General Information + SMS | Baseline Brief Intervention | Baseline Brief Intervention + SMS | Baseline Brief Intervention + 2 Booster Sessions | Baseline Brief Intervention + 2 Booster Sessions + SMS |
|---|---|---|---|---|---|---|
| Started | 63 | 66 | 63 | 66 | 63 | 63 |
| Completed | 62 | 64 | 62 | 65 | 59 | 61 |
| Not completed | 1 | 2 | 1 | 1 | 4 | 2 |
| Withdrew: Pregnancy loss | 1 | 2 | 1 | 1 | 2 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 2 | 1 |
The primary outcome of abstinence will be defined as no self-report of alcohol use in the past 90 days via Timeline FollowBack, measured at 34 weeks gestation.
| Participants | General Information | General Information + SMS | Baseline Brief Intervention | Baseline Brief Intervention + SMS | Baseline Brief Intervention + 2 Booster Sessions | Baseline Brief Intervention + 2 Booster Sessions + SMS |
|---|---|---|---|---|---|---|
| Number of Participants Abstinent From Alcohol as Measured by Timeline FollowBack Calendar Recall | 42 | 47 | 49 | 46 | 44 | 53 |
Healthy birth outcome, using birth outcome data from the state of birth, is defined as a full-term live birth (\>=36 weeks + 6 days) of normal birthweight (\>2500 gms) and with no days in neonatal intensive care.
| Participants | General Information | General Information + SMS | Baseline Brief Intervention | Baseline Brief Intervention + SMS | Baseline Brief Intervention + 2 Booster Sessions | Baseline Brief Intervention + 2 Booster Sessions + SMS |
|---|---|---|---|---|---|---|
| Number of Participants With a Healthy Birth Outcome (Full-term Live Birth of Normal Birthweight, With no Days in NICU) | 47 | 45 | 50 | 54 | 46 | 48 |
Collected over From enrollment (up to 20 weeks pregnant) until the end of follow-up (4 weeks postpartum), up to 44 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| General Information | 0/63 (0%) | 1/63 (1.6%) | 10/63 (15.9%) |
| General Information + SMS | 0/66 (0%) | 2/66 (3%) | 11/66 (16.7%) |
| Baseline Brief Intervention | 0/63 (0%) | 1/63 (1.6%) | 12/63 (19%) |
| Baseline Brief Intervention + SMS | 0/66 (0%) | 1/66 (1.5%) | 11/66 (16.7%) |
| Baseline Brief Intervention + 2 Booster Sessions | 0/63 (0%) | 4/63 (6.3%) | 23/63 (36.5%) |
| Baseline Brief Intervention + 2 Booster Sessions + SMS | 0/63 (0%) | 1/63 (1.6%) | 10/63 (15.9%) |
| Event | General Information | General Information + SMS | Baseline Brief Intervention | Baseline Brief Intervention + SMS | Baseline Brief Intervention + 2 Booster Sessions | Baseline Brief Intervention + 2 Booster Sessions + SMS |
|---|---|---|---|---|---|---|
| Pregnancy LossPregnancy, puerperium and perinatal conditions | 1/63 | 2/66 | 1/63 | 1/66 | 2/63 | 1/63 |
| Hospitalization (high blood pressure/preeclampsia)General disorders | 0/63 | 0/66 | 0/63 | 0/66 | 1/63 | 0/63 |
| Hospitalization (vasa previa)Pregnancy, puerperium and perinatal conditions | 0/63 | 0/66 | 0/63 | 0/66 | 1/63 | 0/63 |
| Event | General Information | General Information + SMS | Baseline Brief Intervention | Baseline Brief Intervention + SMS | Baseline Brief Intervention + 2 Booster Sessions | Baseline Brief Intervention + 2 Booster Sessions + SMS |
|---|---|---|---|---|---|---|
| AnxietyGeneral disorders | 2/63 | 5/66 | 3/63 | 5/66 | 9/63 | 3/63 |
| DepressionGeneral disorders | 2/63 | 1/66 | 5/63 | 4/66 | 9/63 | 4/63 |
| Alcohol use (postpartum)General disorders | 2/63 | 3/66 | 4/63 | 0/66 | 5/63 | 3/63 |
| HypertensionGeneral disorders | 4/63 | 2/66 | 0/63 | 2/66 | 0/63 | 0/63 |
11 people were randomized but did not complete study intervention and assessments due to pregnancy loss (n=8) and participant withdrawal (n=3).
| Age, Customized(Participants) | General Information | General Information + SMS | Baseline Brief Intervention | Baseline Brief Intervention + SMS | Baseline Brief Intervention + 2 Booster Sessions | Baseline Brief Intervention + 2 Booster Sessions + SMS | Total |
|---|---|---|---|---|---|---|---|
| 21 to 26 years old | 14 | 12 | 9 | 8 | 8 | 5 | 56 |
| 27 to 29 years old | 15 | 11 | 15 | 12 | 14 | 14 | 81 |
| 30 to 32 years old | 18 | 18 | 23 | 26 | 18 | 20 | 123 |
| 33 to 35 years old | 15 | 23 | 15 | 19 | 19 | 22 | 113 |
| Sex: Female, Male(Participants) | General Information | General Information + SMS | Baseline Brief Intervention | Baseline Brief Intervention + SMS | Baseline Brief Intervention + 2 Booster Sessions | Baseline Brief Intervention + 2 Booster Sessions + SMS | Total |
|---|---|---|---|---|---|---|---|
| Female | 62 | 64 | 62 | 65 | 59 | 61 | 373 |
| Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | General Information | General Information + SMS | Baseline Brief Intervention | Baseline Brief Intervention + SMS | Baseline Brief Intervention + 2 Booster Sessions | Baseline Brief Intervention + 2 Booster Sessions + SMS | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Asian | 0 | 1 | 1 | 2 | 2 | 3 | 9 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 5 | 7 | 5 | 1 | 4 | 25 |
| White | 55 | 56 | 50 | 55 | 54 | 49 | 319 |
| More than one race | 4 | 1 | 4 | 2 | 2 | 3 | 16 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 0 | 2 | 3 |
| Ethnicity (NIH/OMB)(Participants) | General Information | General Information + SMS | Baseline Brief Intervention | Baseline Brief Intervention + SMS | Baseline Brief Intervention + 2 Booster Sessions | Baseline Brief Intervention + 2 Booster Sessions + SMS | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 5 | 4 | 1 | 3 | 5 | 6 | 24 |
| Not Hispanic or Latino | 57 | 60 | 61 | 62 | 54 | 55 | 349 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Data will be deposited in the National Institute on Alcohol Abuse and Alcoholism Data Archive (NIAAA DA). All collected Individual Participant Data (IPD) at the item level and individual subject level will be shared. The data will be identified only by Global Unique Identifier (GUID; no personally identifiable information will be shared).
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code
Time frame: In accordance with the Notice of NIAAA Data-Sharing Policy for Human Subjects Grants Research Funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) [2nd Revision], Notice Number NOT-AA-19-020, released July 31, 2019: Data will be shared with the general research community 2 years after the grant end date on the initial Notice of Award. However, if a manuscript using study data is accepted for publication prior to the 2-year embargo, the study data specifically used in that manuscript will be shared with the general research community at the time of publication. For this study, the grant end date is August 31, 2024, making the share date August 31, 2026 unless publication occurs prior to that date, in which case published data will be shared at the time of publication. The data are expected to remain available indefinitely unless sharing is limited by currently unforeseen circumstances.
Access criteria: Access to data for research purposes will be provided through the National Data Archive Data Access Committee (NDA DAC). Investigators and institutions seeking data from the NDA will be expected to meet data security measures and will be asked to submit a Data Use Certification, which is co-signed by the investigator and the designated Institutional Official(s) at the NIH-recognized sponsoring institution with a current Federal Wide Assurance (FWA). The procedures associated with data access are described at https://ndar.nih.gov/ndarpublicweb/policies.go#sop4
Data sharing details ↗ · ndar.nih.gov
Ran from May 2023 to primary completion in Aug 2025, 26 months.
Results were first posted in Oct 2026, 1 year 2 months after primary completion.
Of 28 interventional studies with no phase under Fetal Alcohol Spectrum Disorders, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 43. This study's 26 months is close to that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fetal Alcohol Spectrum Disorders →